Coronavirus pandemic: daily updated research and data.
Read more

In our Data Explorer you can see our COVID-19 vaccination data — you can also visualize the latest data on confirmed cases, deaths, and testing.

Open the Data Explorer in a new tab.

Select a group of countries at once: all European countries, 30 largest countries; EU; Americas; OECD.


The Our World in Data COVID vaccination data

To bring this pandemic to an end, a large share of the world needs to be immune to the virus. The safest way to achieve this is with a vaccine. Vaccines are a technology that humanity has often relied on in the past to bring down the death toll of infectious diseases.

Within less than 12 months after the beginning of the COVID-19 pandemic, several research teams rose to the challenge and developed vaccines that protect from SARS-CoV-2, the virus that causes COVID-19.

Now the challenge is to make these vaccines available to people around the world. It will be key that people in all countries — not just in rich countries — receive the required protection. To track this effort we at Our World in Data are building the international COVID-19 vaccination dataset that we make available on this page.

  • Open access: as with all of our data, we are making this dataset openly available, so that everyone can check and use the data that we bring together. You find the vaccination data in our daily-updated repository on GitHub.

Country-by-country data on COVID-19 vaccinations

This page has a number of charts on vaccination. In the box below you can select any country you are interested in — or several, if you want to compare countries.

All charts on this page will then show data for the countries that you selected.

None selected

How many COVID-19 vaccine doses are administered daily?

Daily number of COVID-19 vaccinations administered per 100 people

The following chart shows the daily number of COVID-19 vaccination doses administered per 100 people. This is shown as the rolling seven-day average. Note that this is counted as a single dose, and may not equal the total number of people vaccinated, depending on the specific dose regime (e.g. people receive multiple doses).

Daily number of COVID-19 vaccinations administered

How many COVID-19 vaccination doses have been administered?

The following map and chart show the number of COVID-19 vaccination doses administered per 100 people within a given population. Note that this is counted as a single dose, and may not equal the total number of people vaccinated, depending on the specific dose regime as several available COVID vaccines require multiple doses.

Total number of COVID-19 vaccinations administered

The following chart shows the total number of COVID-19 vaccination doses administered. Note that this is counted as a single dose, and may not equal the total number of people vaccinated, depending on the specific dose regime (e.g. people receive multiple doses).

What share of the population has received at least one dose of the COVID-19 vaccine?

The following chart shows the share of the total population that has received at least one dose of the COVID-19 vaccine. This may not equal the share that are fully vaccinated if the vaccine requires two doses. If a person receives the first dose of a 2-dose vaccine, this metric goes up by 1. If they receive the second dose, the metric stays the same.

Total number of people who have received at least one dose of the COVID-19 vaccine

The following chart shows the total number of people that have received at least one dose of the COVID-19 vaccine. This may not equal the number that are fully vaccinated if the vaccine requires two doses. If a person receives the first dose of a 2-dose vaccine, this metric goes up by 1. If they receive the second dose, the metric stays the same.

What share of the population has been fully vaccinated against COVID-19?

The following chart shows the share of the total population that has been fully vaccinated against COVID-19. This represents the share that have received all doses prescribed by the vaccination protocol. If a person receives the first dose of a 2-dose vaccine, this metric stays the same. If they receive the second dose, the metric goes up by 1.

This data is only available for countries which report the breakdown of doses administered by first and second doses.

Total number of people who have been fully vaccinated against COVID-19

The following chart shows the total number of people that have been fully vaccinated against COVID-19. This represents the number that have received all doses prescribed by the vaccination protocol. If a person receives the first dose of a 2-dose vaccine, this metric stays the same. If they receive the second dose, the metric goes up by 1.

This data is only available for countries which report the breakdown of doses administered by first and second doses.

Vaccination policies

This interactive chart maps government policies on COVID-19 vaccination. Note that this only tracks policies on the availability of vaccinations. It does not track the number of people who have been vaccinated.

Countries are grouped into six categories:

  • No availability
  • Availability for ONE of following: key workers/ clinically vulnerable groups / elderly groups
  • Availability for TWO of following: key workers/ clinically vulnerable groups / elderly groups
  • Availability for ALL of following: key workers/ clinically vulnerable groups / elderly groups
  • Availability for all three plus partial additional availability (select broad groups/ages)
  • Universal availability

Vaccination policy data is sourced from the Oxford Coronavirus Government Response Tracker

This data on vaccination policies is sourced from the Oxford Coronavirus Government Response Tracker (OxCGRT).

This resource is published by researchers at the Blavatnik School of Government at the University of Oxford: Thomas Hale, Anna Petherik, Beatriz Kira, Noam Angrist, Toby Phillips and Samuel Webster.

The tracker presents data collected from public sources by a team of over one hundred Oxford University students and staff from every part of the world.

The data presented here is taken directly from the OxCGRT project; Our World in Data do not track policy responses ourselves, and do not make additions to the tracker dataset.

These charts are regularly updated based on the latest version of the response tracker.

OxCGRT is an ongoing collation project of live data. If you see any inaccuracies in the underlying data, or for specific feedback on the analysis or another aspect of the project please contact OxCGRT team. See the tracker’s notes and guidance on data quality.

Attitudes to COVID-19 vaccinations

The Imperial College London YouGov Covid-19 Behaviour Tracker Data Hub gathers global insights on people’s behaviors in response to COVID-19. This survey covers public behaviors and attitudes ranging from mask-wearing to self-isolation, social distancing, symptoms and testing.

The following chart shows monthly data on public willingness to receive the COVID-19 vaccine.

Data represents the share of respondents that agree with the following statement: “If a COVID-19 vaccine were made available to me this week, I would definitely get it.” Respondents were presented with a 1 to 5 scale, ranging from “Strongly agree” (1) to “Strongly disagree” (5). We consider responses of 1 or 2 to be in agreement with the statement.

Vaccine development: vaccines approved for use and in clinical trials

The speed at which the first COVID-19 vaccines were developed was extraordinary. We have previously looked into the history of vaccine development. The measles vaccine was found relatively rapidly: it took only 10 years from the discovery of the pathogen to the development of the first vaccine. But for typhoid it took more than a century, and for some diseases for which we’ve known the pathogens for more than a century (like malaria) we still haven’t found an effective vaccine.

The development of a vaccine against COVID-19 has been much faster than the development of any other vaccine. Within less than a year several successful vaccines have already been announced and were approved for use in some countries. 

The hope is that even more manufacturers develop vaccines for COVID-19. This will be important because eventually a very large share of the world population needs to receive a COVID-19 vaccine.

We are on the way to several vaccines against COVID-19 – vaccine trackers monitor the progress:

Several institutions maintain websites on which they list COVID-19 candidate vaccines that are currently being developed:

Source information country by country

You can download the full dataset alongside the detailed source descriptions on GitHub.

Note that other countries may have also started vaccination campaigns—we’ll add them to our maps and charts as soon as numbers are verifiable based on public official sources.

We do not include participants in the vaccine arm of clinical trials, as this data is not available for many of the hundreds of trials currently taking place.

The population estimates we use to calculate per-capita metrics are all based on the last revision of the United Nations World Population Prospects. The exact values can be viewed in our GitHub repository.

LocationSourceLast observation dateVaccines
ArgentinaMinistry of HealthJanuary 26, 2021Sputnik V
AustriaMinistry of HealthJanuary 26, 2021Pfizer/BioNTech
BahrainMinistry of HealthJanuary 20, 2021Pfizer/BioNTech, Sinopharm
BelgiumSciensanoJanuary 25, 2021Pfizer/BioNTech
BermudaMinistry of HealthJanuary 16, 2021Pfizer/BioNTech
BrazilRegional governments via Coronavirus BrasilJanuary 26, 2021Sinovac
BulgariaMinistry of HealthJanuary 26, 2021Moderna, Pfizer/BioNTech
CanadaCOVID-19 Canada Open Data Working GroupJanuary 26, 2021Moderna, Pfizer/BioNTech
ChileDepartment of Statistics and Health InformationJanuary 26, 2021Pfizer/BioNTech
ChinaNational Health CommissionJanuary 20, 2021CNBG, Sinovac
Costa RicaNational Health CommissionJanuary 25, 2021Pfizer/BioNTech
CroatiaMinistry of HealthJanuary 25, 2021Pfizer/BioNTech
CyprusMinistry of HealthJanuary 22, 2021Pfizer/BioNTech
CzechiaMinistry of HealthJanuary 26, 2021Moderna, Pfizer/BioNTech
DenmarkStatens Serum InstitutJanuary 25, 2021Moderna, Pfizer/BioNTech
EcuadorGovernment of EcuadorJanuary 22, 2021Pfizer/BioNTech
EnglandGovernment of the United KingdomJanuary 25, 2021Oxford/AstraZeneca, Pfizer/BioNTech
EstoniaNational Health BoardJanuary 26, 2021Pfizer/BioNTech
FinlandFinnish Institute for Health and WelfareJanuary 26, 2021Pfizer/BioNTech
FranceMinistry of HealthJanuary 26, 2021Pfizer/BioNTech
GermanyRobert Koch InstitutJanuary 25, 2021Moderna, Pfizer/BioNTech
GibraltarGovernment of GibraltarJanuary 25, 2021Pfizer/BioNTech
GreeceMinistry of HealthJanuary 26, 2021Pfizer/BioNTech
HungaryGovernment of HungaryJanuary 25, 2021Pfizer/BioNTech
IcelandDirectorate of HealthJanuary 25, 2021Moderna, Pfizer/BioNTech
IndiaMinistry of HealthJanuary 26, 2021Covaxin, Covishield
IndonesiaMinistry of HealthJanuary 26, 2021Sinovac
IrelandHeath Service ExecutiveJanuary 24, 2021Pfizer/BioNTech
Isle of ManIsle of Man GovernmentJanuary 25, 2021Pfizer/BioNTech
IsraelGovernment of IsraelJanuary 26, 2021Moderna, Pfizer/BioNTech
ItalyExtraordinary commissioner for the Covid-19 emergencyJanuary 26, 2021Pfizer/BioNTech
KuwaitMinistry of HealthDecember 28, 2020Pfizer/BioNTech
LatviaNational Health ServiceJanuary 25, 2021Pfizer/BioNTech
LithuaniaMinistry of HealthJanuary 26, 2021Moderna, Pfizer/BioNTech
LuxembourgGovernment of LuxembourgJanuary 25, 2021Pfizer/BioNTech
MaltaMinistry of HealthJanuary 25, 2021Pfizer/BioNTech
MexicoSecretary of HealthJanuary 26, 2021Pfizer/BioNTech
NetherlandsNational Institute for Public Health and the EnvironmentJanuary 26, 2021Moderna, Pfizer/BioNTech
Northern CyprusMinistry of HealthJanuary 22, 2021Pfizer/BioNTech, Sinovac
Northern IrelandGovernment of the United KingdomJanuary 25, 2021Oxford/AstraZeneca, Pfizer/BioNTech
NorwayNorwegian Institute of Public HealthJanuary 25, 2021Pfizer/BioNTech
OmanMinistry of HealthJanuary 26, 2021Pfizer/BioNTech
PanamaMinistry of HealthJanuary 24, 2021Pfizer/BioNTech
PolandMinistry of HealthJanuary 25, 2021Pfizer/BioNTech
PortugalNational Health ServiceJanuary 26, 2021Pfizer/BioNTech
RomaniaGovernment of RomaniaJanuary 26, 2021Pfizer/BioNTech
RussiaRussian Direct Investment FundJanuary 13, 2021Sputnik V
Saudi ArabiaSaudi Health CouncilJanuary 17, 2021Pfizer/BioNTech
ScotlandGovernment of the United KingdomJanuary 25, 2021Oxford/AstraZeneca, Pfizer/BioNTech
SerbiaGovernment of SerbiaJanuary 26, 2021Pfizer/BioNTech, Sinopharm, Sputnik V
SeychellesExtended Programme for ImmunisationJanuary 25, 2021Sinopharm
SingaporeMinistry of HealthJanuary 22, 2021Pfizer/BioNTech
SlovakiaMinistry of HealthJanuary 25, 2021Pfizer/BioNTech
SloveniaNational Institute of Public Health, via SledilnikJanuary 25, 2021Pfizer/BioNTech
SpainMinistry of HealthJanuary 26, 2021Moderna, Pfizer/BioNTech
SwedenPublic Health Agency of SwedenJanuary 25, 2021Pfizer/BioNTech
SwitzerlandFederal Office of Public HealthJanuary 24, 2021Pfizer/BioNTech
TurkeyCOVID-19 Vaccine Information PlatformJanuary 26, 2021Sinovac
United Arab EmiratesNational Emergency Crisis and Disaster Management AuthorityJanuary 26, 2021Pfizer/BioNTech, Sinopharm
United KingdomGovernment of the United KingdomJanuary 25, 2021Oxford/AstraZeneca, Pfizer/BioNTech
United StatesCenters for Disease Control and PreventionJanuary 26, 2021Moderna, Pfizer/BioNTech
WalesGovernment of the United KingdomJanuary 25, 2021Oxford/AstraZeneca, Pfizer/BioNTech

Sign up for regular updates from Our World in Data


→ If you want to keep up-to-date with on our work on COVID-19, and the many other topics we cover you can sign up to our newsletter.